Breaking News
Get 45% Off 0
Selloff or market correction? Either way, here's what to do next
See Overvalued Stocks

DexCom (DXCM) Stock Moves -1.89%: What You Should Know

By Zacks Investment ResearchStock MarketsMar 12, 2020 05:45AM ET
www.investing.com/analysis/dexcom-dxcm-stock-moves-189-what-you-should-know-200515634
DexCom (DXCM) Stock Moves -1.89%: What You Should Know
By Zacks Investment Research   |  Mar 12, 2020 05:45AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
US500
-1.76%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
DJI
-1.48%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

In the latest trading session, DexCom (DXCM) closed at $247.64, marking a -1.89% move from the previous day. This move was narrower than the S&P 500's daily loss of 9.51%. Elsewhere, the Dow lost 9.99%, while the tech-heavy Nasdaq lost 9.44%.

Coming into today, shares of the medical device company had gained 2.61% in the past month. In that same time, the Medical sector lost 12.7%, while the S&P 500 lost 18.22%.

DXCM will be looking to display strength as it nears its next earnings release. In that report, analysts expect DXCM to post earnings of $0.11 per share. This would mark year-over-year growth of 320%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $357.53 million, up 27.46% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $2.25 per share and revenue of $1.78 billion, which would represent changes of +22.28% and +20.32%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for DXCM. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 21.08% higher. DXCM currently has a Zacks Rank of #1 (Strong Buy).

Investors should also note DXCM's current valuation metrics, including its Forward P/E ratio of 112.19. This valuation marks a premium compared to its industry's average Forward P/E of 28.62.

Investors should also note that DXCM has a PEG ratio of 3.06 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 2.23 as of yesterday's close.

The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 53, which puts it in the top 21% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.



DexCom, Inc. (DXCM): Free Stock Analysis Report

Original post

Zacks Investment Research

DexCom (DXCM) Stock Moves -1.89%: What You Should Know
 

Related Articles

DexCom (DXCM) Stock Moves -1.89%: What You Should Know

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email